Cervantes Corp Ltd

Puma Biotechnology reports $56.1M net NERLYNX revenue in Q3'24, a ~9% increase from Q3'23 and ~26% from Q2'24. 2,723 ex-factory bottles sold, a ~5% decline from Q3'23 but an ~8% increase from Q2'24. ~65% of patients started at a reduced dose. Forward-looking statements involve risks, including COVID-19 impact and regulatory filings.

The FDA proposed removing oral phenylephrine from the market due to its ineffectiveness as a nasal decongestant, launching a six-month public comment period. CVS stopped selling products with phenylephrine last year after an FDA advisory committee declared it ineffective, while other major pharmacies still stock it. The FDA's proposal targets only oral forms of the drug, not nasal sprays. The Consumer Healthcare Products Association opposes the move, arguing that phenylephrine should remain available as a self-care option.

The Hair Lab by Strands, founded by Eric Delapenha, expands retail footprint to CVS’ Beauty IRL. The brand aims to offer diagnostic tools and personalized hair care solutions, leveraging biological data for customization. After launching online in 2020, Strands partnered with Walmart to create The Hair Lab, which debuted in 2022.

Medtronic settled a lawsuit over pulse oximeters' accuracy for darker skin, agreeing to provide labels and brochures to California hospitals. The FDA has delayed guidance on pulse oximeter accuracy since 2021, now prioritizing it for fiscal year 2025.

Starting March 31, 2025, OA REMS companies must provide pre-paid drug mail-back envelopes to outpatient pharmacies and opioid dispensers upon request. This FDA-approved update aims to safely dispose of unused or expired opioid analgesics, with revised Patient Guides and new Patient Education Sheets included in each mail-back envelope.

Jay Lefkowitz and Andrew Soukup, representing Haleon and Procter & Gamble, secured a dismissal for their clients in an MDL involving phenylephrine-based cold medicine. The dismissal was based on preemption by federal law and lack of standing for RICO claims. The collaborative defense effort included multiple law firms and in-house counsel, emphasizing the FDA's exclusive authority over drug efficacy determinations.

GoodRx launched an e-commerce platform with Opill, the first OTC birth control pill in the U.S., offering home delivery. The platform also introduced affordability programs for Pfizer's menopause hormone therapies, amid rising medication costs and the 'Pink Tax' in healthcare.

REBBL launched a 26 g Protein Shake with low environmental impact, Nurri released lactose-free protein milk shakes, Nature’s Bounty expanded its women’s health portfolio with Intimacy Booster, Healthy pH Balance, and Hair Growth Gummies, Boka introduced pre and probiotic supplements for oral and gut health, Force Factor and Nutrition21 partnered for Hair Growth Accelerator supplements, Jarrow Formulas launched Multi+ multivitamins for men, women, and mood support, and Happy Aging released NAD+ Longevity Shots for skin health and cellular detoxification.

Walgreens CEO Tim Wentworth announced 1,200 store closures over three years due to a quarter of the chain's stores being unprofitable. This follows CVS's recent layoffs, as both chains face issues with overexpansion, changing shopper habits, and strained relationships with health insurers. Both companies are reconsidering their roles and focusing on cost-saving measures, including store closures and job cuts. They are also exploring new structures for prescription reimbursement to improve profitability.

Ivo Abraham discusses early biosimilar research challenges in the US, emphasizing the need for affordable drug strategies and volume contracts. He recalls initial skepticism and the shift towards equity in biosimilar development.